
Release date: 2025-01-20 09:44:20 Article From: Lucius Laos Recommended: 285
Avatrombopag is a novel oral thrombopoietin receptor agonist, and its dosage has attracted much attention.
Knowing the correct dosage of avatrombopag is essential to ensure the effectiveness of the treatment.
The usual adult dose of avatrombopag usually depends on the patient's specific situation and the purpose of treatment. In general, in most clinical situations, the recommended starting dose is 20 mg once daily.
Depending on the patient's platelet count response, the dose may need to be adjusted. If the platelet count does not reach the desired level after treatment, your doctor may consider increasing the dose, but usually not more than the upper limit of 50 mg once a day. Conversely, if the platelet count is too high, the dose should be reduced appropriately.
For special populations such as the elderly and people with liver and kidney insufficiency, the dose of avatrombopag needs to be adjusted according to the specific physical condition of the patient. The doctor will make a comprehensive evaluation based on the patient's liver and kidney function indicators, age and other factors to determine the most appropriate dose.
In addition to dosage issues, there are many other aspects that need to be paid attention to when taking avatrombopag.
Avatrombopag should be started at a certain time before surgery or before a specific medical procedure to ensure that the desired platelet count is achieved at critical moments. The exact timing should be guided by your doctor.
Avatrombopag may interact with other medications, affecting its effectiveness or increasing the risk of side effects. Therefore, while taking avatrombopag, patients should inform their doctor of all medications they are taking, including prescription medications, over-the-counter medications, and health supplements.
While taking avatrombopag, patients need regular blood tests to monitor changes in platelet counts. The doctor will also arrange other necessary tests depending on the patient's specific situation.
The recommended dose of avatrombopag depends on the patient's specific situation, and there are several aspects to be taken into account. Patients should strictly follow the doctor's instructions, take their medications on time, and monitor them regularly. For any medication questions or discomfort, patients should communicate with their doctor in time for professional advice and treatment.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:3502025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:5512024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:3362025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:3512025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:3262025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:3922025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:3262025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:3002025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643